Biotech Startups

Booster Therapeutics develops small-molecule medicines that directly activate the cell's 20S proteasome to restore protein quality-control and clear disease-causing proteins, using its structure-based DGRADX platform combining high-throughput screening, X-ray crystallography, and computational tools. The company is building a multi-disease pipeline initially focused on neurodegenerative diseases.

1 investor

Bora Pharmaceuticals is a pharmaceutical services company offering CDMO (contract development and manufacturing) for both small molecule and large molecule/biologics products, alongside its own drug development focused on specialty pharma and rare diseases. Founded in 2007 and headquartered in Taiwan, it serves pharmaceutical and biotech partners globally.

1 investor

Borea Therapeutics develops gene therapy delivery technologies based on a proprietary AAV conjugation platform targeting neurological and genetic diseases. The company serves the therapeutic biotechnology market with precision neuronal targeting and advanced delivery strategies.

1 investor

Borealis develops RNA medicines to treat kidney diseases. The company was founded by the team behind Chinook Therapeutics, which Novartis acquired in 2023, and focuses on kidney disease indications with unmet medical need.

1 investor

Boston Cell Standards develops calibration and quality-control products (IHCalibrators and IHControls) for immunohistochemistry (IHC) laboratories, used for assay validation, instrument alignment, troubleshooting, and proficiency testing. Its standards serve clinical and research labs and drug developers to maintain consistent IHC test results across sites and trial phases for accurate patient diagnosis and treatment stratification.

1 investor

Botanical Solution Inc (BSI) uses a patented plant tissue culture platform to produce advanced botanical materials from the Chilean tree Quillaja saponaria, offering a sustainable supply of botanical active ingredients. Its products include the biofungicide Quillibrium (sold in Chile as BotriStop) for high-value crops and the vaccine adjuvant QS-21 for pharmaceutical use.

1 investor

Boulevard Bio is a clinical-stage precision immunology company developing multi-specific antibody therapies for B cell-driven autoimmune diseases, with a lead program targeting IgA nephropathy. Its pipeline aims to modify disease at the source for conditions such as IgAN, lupus, and Sjögren's disease.

1 investor

Bovotica develops technology that modulates the rumen microbiome of cattle to reduce methane emissions and improve production efficiency for farmers. It targets the cattle industry with a focus on sustainability and climate impact.

1 investor

BoxOne Ventures is an early-stage investment firm backing founders across biotechnology, food, markets, longevity, intelligence, and clean energy. It focuses on supporting emerging talent to build technologies that improve quality of life.

1 investor

BPC Instruments develops automated laboratory instruments and software for gas measurement, respirometry, and biological process analysis, used in biogas, biodegradability, nutrition, wastewater, and biohydrogen research. It serves laboratories, research institutes, and industrial customers worldwide.

1 investor

BrainStorm Cell Therapeutics develops NurOwn, an autologous MSC-NTF cellular therapy platform aimed at treating neurodegenerative diseases with limited treatment options. Its cell therapy is investigational and not yet FDA approved.

1 investor

BrainsWay develops Deep TMS (Transcranial Magnetic Stimulation) systems for treating psychiatric and neurological conditions including depression, OCD, and smoking addiction. The platform includes brain-targeting stimulators with patented H-Coils, patient management capabilities, and clinical research-grade variants for healthcare providers.

1 investor

Bramante Bio manufactures AI-driven robotic instruments and reagents for life sciences research and manufacturing. The company designs hardware that integrates with modern software stacks and provides direct engineering support.

1 investor

Brandaris Therapeutics is a translational-stage biotech developing first-in-class and best-in-class small-molecule therapies for neuropsychiatric disorders such as depression and anxiety, using a differentiated approach to receptor pharmacology. Its drug candidates aim to provide rapid-onset, durable efficacy with improved side-effect profiles for patients with mental health disorders.

1 investor

Breakpoint Therapeutics is a biotech company focused on oncology drug discovery and development centered on DNA damage response (DDR) mechanisms. It was spun off from Evotec's DDR projects to advance an independent cancer drug pipeline.

1 investor

Breakthru is a drug development company that applies medicinal chemistry expertise to accelerate the discovery of breakthrough medicines, emphasizing data-driven decision-making about compound viability.

1 investor

Breath Diagnostics develops OneBreath, a non-invasive breath test that captures volatile organic compounds from a single exhale and analyzes them with microreactor chemistry and mass spectrometry to detect early-stage lung cancer. The test is aimed at at-risk patients such as smokers and is designed for use in clinics, pharmacies, and community health settings.

1 investor

Breathe BioMedical develops a breath analytics test for early breast cancer detection, intended as an adjunct to mammography screening particularly for women with dense breast tissue. The company works in the medtech and diagnostics field, using exhaled breath signatures to identify disease before symptoms appear.

1 investor

1 investor

Brevel develops scalable production solutions for light-responsive biological systems, serving ingredient companies, biotechnology firms, plant cell culture developers, food manufacturers, cosmetics companies, and pharmaceutical innovators.

1 investor

Breye Therapeutics is a biopharmaceutical company developing medicines for ophthalmologic and metabolic diseases, leveraging expertise in clinical development, manufacturing, and regulatory pathways. The company focuses on bringing novel therapies from early-stage discovery through late-stage development and product approval.

1 investor

Bridge Farm Nurseries grows houseplants for the wholesale market with a focus on sustainable cultivation practices. The company operates an industry-leading glasshouse facility established over several decades of growth and diversification.

1 investor

Bridgewest Ventures is a venture capital firm focused on deep technology investments in New Zealand, leveraging the infrastructure and expertise of the Bridgewest Group to help founders scale innovative research from lab to global markets. The firm targets specific verticals including AI, life sciences, software, and hardware, providing capital, strategic guidance, and access to international networks and regulatory infrastructure.

1 investor

Brink Biologics provides NK-92 cell lines and assay panels for antibody-dependent cell-mediated cytotoxicity (ADCC) testing in therapeutic antibody development. The company offers proprietary Neukopanel cell lines and related services to pharmaceutical and biotechnology companies developing cancer and immunotherapy treatments.

1 investor